Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
$0.01
$0.00
$0.00
$0.01
$116K10.3554 shs1 shs
NEPTF
Neptune Wellness Solutions
$0.03
$0.02
$0.00
$0.12
$136K-2.627,709 shsN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
$0.00
$0.00
$0.21
$36KN/A26,223 shs2,000 shs
OREXQ
Orexigen Therapeutics
$0.01
+35.9%
$0.01
$0.00
$0.16
$100K4.9880,439 shs60,300 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00%0.00%+9,900.00%+9,900.00%+9,900.00%
NEPTF
Neptune Wellness Solutions
0.00%0.00%+113.57%+498.00%+2,989,900.00%
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
0.00%0.00%0.00%0.00%0.00%
OREXQ
Orexigen Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
$0.01
$0.00
$0.00
$0.01
$116K10.3554 shs1 shs
NEPTF
Neptune Wellness Solutions
$0.03
$0.02
$0.00
$0.12
$136K-2.627,709 shsN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
$0.00
$0.00
$0.21
$36KN/A26,223 shs2,000 shs
OREXQ
Orexigen Therapeutics
$0.01
+35.9%
$0.01
$0.00
$0.16
$100K4.9880,439 shs60,300 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00%0.00%+9,900.00%+9,900.00%+9,900.00%
NEPTF
Neptune Wellness Solutions
0.00%0.00%+113.57%+498.00%+2,989,900.00%
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
0.00%0.00%0.00%0.00%0.00%
OREXQ
Orexigen Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00
N/AN/AN/A
NEPTF
Neptune Wellness Solutions
2.00
HoldN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
0.00
N/AN/AN/A
OREXQ
Orexigen Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/AN/A
NEPTF
Neptune Wellness Solutions
$52.62M0.00N/AN/A($91.90) per share0.00
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/AN/AN/AN/AN/A
OREXQ
Orexigen Therapeutics
$33.71M0.00N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
-$2.11MN/A0.00N/AN/AN/AN/AN/A
NEPTF
Neptune Wellness Solutions
-$60.46M-$106.72N/AN/AN/AN/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/A0.00N/AN/AN/AN/AN/AN/A
OREXQ
Orexigen Therapeutics
-$24.52MN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/A
NEPTF
Neptune Wellness Solutions
N/AN/AN/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/AN/AN/AN/A
OREXQ
Orexigen Therapeutics
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/A
NEPTF
Neptune Wellness Solutions
11.72%
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/A
OREXQ
Orexigen Therapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
211.63 million8.35 millionNot Optionable
NEPTF
Neptune Wellness Solutions
1304.53 million4.30 millionN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
1,70012.95 millionN/ANot Optionable
OREXQ
Orexigen Therapeutics
13218.89 millionN/ANot Optionable

Recent News About These Companies

Axsome Therapeutics Inc (AXSM)
Heron Therapeutics Inc HRTX
Regulation of Appetite to Treat Obesity

New MarketBeat Followers Over Time

Adhera Therapeutics stock logo

Adhera Therapeutics OTCMKTS:ATRX

$0.01 0.00 (0.00%)
As of 09/5/2025

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

Neptune Wellness Solutions OTC:NEPTF

$0.03 0.00 (0.00%)
As of 09/8/2025

Neptune Wellness Solutions Inc. operates as an integrated health and wellness company. It builds a portfolio of lifestyle brands and consumer packaged goods products under the Biodroga Neutraceuticals, Forest Remedies, Ocean Remedies, Neptune Wellness, Mood Ring, PanHash, Sprout, Nosh, and NurturMe brands. The company offers turnkey product development and supply chain solutions to business customers in various health and wellness verticals, such as legal cannabis and hemp, nutraceuticals, and white label consumer packaged goods. It is also involved in the extraction, purification, formulation, and manufacturing of health and wellness products, such as omega-3 and hemp-derived products under various delivery forms, such as soft gels, liquids, capsules, vape pens, sprays, topicals, sachets, tinctures, concentrates, edibles, and beverages, as well as hand sanitizers, non-contact thermometers, and gloves. In addition, the company offers Maxsimil, an omega-3 fatty acid delivery technology that uses enzymes that mimic the natural human digestive system to predigest omega-3 fatty acids. It has a collaboration agreement with International Flavors & Fragrances Inc. to co-develop hemp-derived CBD products for the mass retail, and health and wellness markets. The company was incorporated in 1998 and is headquartered in Laval, Canada.

NephroGenex stock logo

NephroGenex OTCMKTS:NRXGQ

NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.

Orexigen Therapeutics OTCMKTS:OREXQ

$0.0053 +0.00 (+35.90%)
As of 05/31/2019

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.